Skip to main content

$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
Register to track IMU and receive email alerts.

Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx

StockBot

416,823 posts

IMU released this announcement to the ASX on 4 January 2022, 9:30. The announcement is marked as price sensitive, and is 2 page(s) in length and 96.13kb in size.

You can view all announcements from IMU and see how they appear on a price chart on the announcements page.

At the date of this announcement, IMU was 3.189% short sold according to ASIC data. It was ranked the 46th most shorted stock on the ASX. It is now ranked as the 41st most shorted stock on the ASX with 5.254% of total shares short sold as of the latest reported data (19 June 2025).

Other Recent Announcements from IMU
Change of Director's Interest Notice 30 June 2023, 16:33
HER-Vaxx induced antibodies correlated with tumour reduction 30 June 2023, 8:40
Imugene PD1-Vaxx patent extended to 2040 29 June 2023, 8:39
Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx 4 January 2022, 9:30
Imugene adds industry leaders to senior management team 4 January 2022, 9:27
Notice Under Section 708A 23 December 2021, 17:14
Notification regarding unquoted securities - IMU 23 December 2021, 17:11
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track IMU and receive email alerts.